Table 2.
Number of active PD drug trials by therapeutic category and phase (as of January 31, 2024, ClinicalTrials.gov)
| Category | Phase 1 | Phase 2 | Phase 3 | Total | % |
| Anti-inflammatory | 5 | 2 | 0 | 7 | 5% |
| Antioxidant | 0 | 2 | 0 | 2 | 1% |
| Cell therapy | 11 | 0 | 0 | 11 | 8% |
| Energy and mitochondria | 0 | 4 | 0 | 4 | 3% |
| GBA | 2 | 4 | 1 | 7 | 5% |
| GLP-1R agonist | 1 | 3 | 1 | 5 | 4% |
| Kinase inhibitor | 1 | 4 | 0 | 5 | 4% |
| LRRK2 | 1 | 1 | 0 | 2 | 1% |
| Microbiome/GIT | 2 | 3 | 1 | 6 | 4% |
| Neurotrophic factors | 2 | 2 | 0 | 4 | 3% |
| Other DMT | 2 | 6 | 0 | 8 | 6% |
| Targeting aSN | 1 | 8 | 0 | 9 | 7% |
| Dopamine agonist | 3 | 4 | 6 | 13 | 10% |
| Dopaminergic – LD reformulation | 1 | 1 | 3 | 5 | 4% |
| Dopaminergic other | 4 | 0 | 1 | 5 | 4% |
| Non-DA adrenergic | 0 | 3 | 1 | 4 | 3% |
| Non-DA cholinergic | 1 | 3 | 1 | 5 | 4% |
| Non-DA glutamatergic | 1 | 8 | 0 | 9 | 7% |
| Non-DA serotonergic | 1 | 7 | 1 | 9 | 7% |
| Non-DA other | 2 | 14 | 0 | 16 | 12% |
| Total | 41 | 79 | 16 | 136 | 100% |